Even when the combination treated mice are given a 10-fold greater tumor challenge than the mice receiving FVAX alone, high CD8 to Treg ratios are evident at Day-25 in the groups receiving α4-1BB (Figure 2F). Here, CD8A is linked to neoplasm.